Browsing Tag
Zaynich
4 posts
Wockhardt delivers strong FY25 EBITDA, but net loss persists amid US restructuring drag
Wockhardt posts a 67% EBITDA jump in FY25, but Q4 PAT remains negative. Find out how novel antibiotics like Zaynich and Miqnaf are shaping investor sentiment.
Wockhardt’s Zaynich achieves record-breaking 96.8% clinical cure rate in cUTI Phase III trial
Wockhardt Limited has announced a major breakthrough in the treatment of complicated urinary tract infections (cUTI) with its…
Wockhardt sees Q2 revenue surge, driven by antibiotic innovation and biosimilar expansion
Wockhardt Limited, a leading pharmaceutical and biotechnology company, released its second-quarter financial results for the fiscal year 2024-25,…
Miracle cure: Wockhardt’s experimental drug defeats deadly superbug in dramatic recovery
Wockhardt Limited announced that its investigational drug Zaynich (Zidebactam/Cefepime) has successfully treated a complex case of bacterial meningitis…